Re: Scientists Demonstrate Investigational MS Drug Down Regulates t...

Cytoreg® inhibits growth and proliferation of human adenocarcinoma
cells via

induction of apoptosis



Weston, Florida.

January 14, 2006



Cytorex Biosciences, Inc. (Cytorex), a Florida based biotechnology
company,

announced today the publication in the January 2006 issue of the
Journal of

Carcinogenesis, of a research report related to in-vitro efficacy
testing in

cancer cell lines and normal cell lines, with Cytoreg®, their lead

anti-cancer compound.



The title of the publication is: "Cytoreg® inhibits growth and
proliferation

of human adenocarcinoma cells via induction of apoptosis". The
corresponding

author is James Kumi-Diaka, DVM, PhD, from Florida Atlantic University

(FAU), and the co-authors of the report are: Manzur Hassanhi, MD, PhD ,


professor of Immunology and Cancer Research Scientist, from the
University

of Zulia (Venezuela), Brown Jayaan(FAU), Kendra Merchant (FAU) , Carlos
M

Garcia (Cytorex), and William Jimenez (Cytorex)



Abstract: "Cancer is one of the devastating neovascular diseases that

incapacitate so many people the world over. Recent reports from the
National

Cancer Institute indicate some significant gain therapy and cancer

management as seen in the increase in the 5-year survival rate over the
past

two decades. Although near-perfect cure rate have been reported in the

early-stage disease, these data reveal high recurrence rate and serious
side

effects including second malignancies and fatalities. Most of the
currently

used anticancer agents are only effective against proliferating cancer

cells. Thus attention has been focused on potential anti-cancer agents

capable of killing cancer cells independent of the cell cycle state, to


ensure effective elimination of most cancer cells. The objective of
this

study was to test the chemosensitivity and potential mechanism of
action of

a novel cancer drug, Cytoreg®, in a panel of human cancer cells.
Methods:

the study was performed using a series of bioassays including Trypan
blue

exclusion, MTS Growth inhibition, LDH-cytotoxicity, TUNEL-Terminal DNA

fragmentation Apoptosis Assay, and the Caspase protease CPP32 activity

assays. Results: Cytoreg® induced significant dose- and time-dependent


inhibition of growth in all the cells; with significant differences in

chemosensitivity (P 1:300). Cytoreg®-induced caspase protease-3
(CPP32)

activation significantly and positively correlated with apoptosis
induction

and growth inhibition; thus implicating CPP32 as the principal death
pathway

in Cytoreg®-induced apoptosis. Conclusion: Cytoreg® exerted a
dose-and

time-dependent growth inhibitory effect in all the target cells through


induction of apoptosis via the CPP32 death pathway, independent of
hormonal

sensitivity of the cells. The present data indicate that not only could


CPP32 provide a potential target for regulation of Cytoreg®-induced

apoptosis but also that Cytoreg® could play a significant role in

chemotherapeutic regimen in many human malignant tumors."



"This is the first of several research reports about Cytoreg® we
plan to

Submit, during 2006. to peer-reviewed journals", said Dr. James
Kumi-Diaka,

Professor of Biology of cancer at Florida Atlantic University in Davie,


Florida.



"Cytoreg® has great potential as an anti-cancer compound, and
additional

research has shown that this compound's toxicity level is very low if


compared with current approved chemotherapeutical agents", indicated
Dr.

Mansur Hassanhi, Professor of Immunology and Cancer Research Scientist
of

the University of Zulia (Maracaibo-Venezuela).



Both Kumi-Diaka and Hasanhi, have lead since 2003 a multinational
research

team involved in the discovery of Cytoreg® as an anti-cancer agent.



According to Cytorex's Vice-President & CFO, William Jimenez, who is
also a

co-author of this research report, "Cytoreg® is a therapeutic agent
for

cellular regulation, with antineoplastic properties which may also be
used

to fight immunological diseases. Cytoreg® constitutes a balanced
mixture of

strong and weak acids in an aqueous medium; resembling a buffer without


using salts. Cytoreg® is transferred into a cellular system through
ionic

transport due to its low molecular weight, where each ion acts
concurrently

in cells, turning Cytoreg® into a highly efficient "smart-drug."
Cytoreg®'s

numerous mechanisms of action are exerted through the cellular
membrane".



A complete PDF version of the report is can be accessed through the
Journal

of Carcinogenesis web page:



http://www.carcinogenesis.com/content/pdf/1477-3163-5-1.pdf


For more information, please contact: Carlos M. Garcia, MEng., Director
&

COO of Cytorex Biosciences, Inc. at 954-993-4941 or send an email
message to:
info@@cytorex.com.

.

Relevant Pages

  • Re: Amalgams Cause Mercury Poisoning and Mark Thorsons lies
    ... Did you prove that his idea about anaerobiosis of cancer cells ... ferment of respiration, which the Caroline Institute ... The discovery for which the Nobel Prize for Physiology or Medicine is to be ...
    (misc.health.alternative)
  • Re: Amalgams Cause Mercury Poisoning and Mark Thorsons lies
    ... Did you prove that his idea about anaerobiosis of cancer cells ... I did prove that he was not awarded the Nobel prize ... ferment of respiration, which the Caroline Institute ...
    (misc.health.alternative)
  • Confucius and cancer
    ... in 1931 for his research on cellular respiration, ... ?The growth of cancer cells is initiated by a relative lack of oxygen. ... earthly weaknesses than the man or woman who thus lives. ...
    (soc.culture.china)
  • What of the Second Law?
    ... Can an *unaided* coil of wire generate a voltage, ... ?The growth of cancer cells is initiated by a relative lack of oxygen. ... Cancer cannot live in an oxygen-rich environment? ...
    (talk.origins)
  • =?iso-8859-1?q?"Cytoreg=AE_inhibits_growth_and_proliferation_of_human_adenocarcinoma_cells_v
    ... Cytorex Biosciences, Inc., a Florida based biotechnology ... of a research report related to in-vitro ... Cancer Research Scientist, from the University of Zulia, ... effective against proliferating cancer cells. ...
    (soc.retirement)